Loans and receivables included €1,390 million (2016: €1,770 million) in bank deposits and €108 million (2016: €305 million) in commercial paper.

The debt instruments classified as available-for-sale financial assets included capital of €605 million (2016: €612 million) provided to Bayer-Pensionskasse VVaG (Bayer-Pensionskasse) for its effective initial fund, and jouissance right capital (Genussrechtskapital) of €152 million (2016: €154 million), also provided to Bayer-Pensionskasse. Also reported in this category were investments of €1,497 million (2016: €3,513 million) in money market funds.

The equity instruments reported as available-for-sale financial assets included the €101 million (2016: €98 million) investment in CRISPR Therapeutics AG, Switzerland, along with €35 million (2016: €32 million) in instruments whose fair value could not be determined from a stock exchange or other market price or by discounting reliably determinable future cash flows. These equity instruments were recognized at cost.

Receivables under lease agreements relate to finance leases where Bayer is the lessor and the economic owner of the leased assets is the lessee. These receivables comprised expected lease payments of €15 million (2016: €39 million), including €2 million (2016: €31 million) in interest. Of the expected lease payments, €3 million (2016: €1 million) is due within one year, €10 million (2016: €2 million) within the following four years and €2 million (2016: €36 million) in subsequent years.